

Topic	BEXSERO®	TRUMENBA®
<b>Manufacturer</b>	GSK <a href="#">Prescribing Info (FDA)</a>	Pfizer <a href="#">Prescribing Info (FDA)</a>
<b>Protects Against</b>	Invasive meningococcal disease caused by <i>N. meningitidis</i> serogroup B	Invasive meningococcal disease caused by <i>N. meningitidis</i> serogroup B
<b>Approved Ages</b>	10 - 25 years	10 - 25 years
<b>Funding Source</b>		
<b>Routine schedule<sup>1</sup></b>	<p><b>Children:</b>  <u>Routine Risk:</u> 2-dose series <math>\geq</math> 6 months apart at age 16-18*; use <a href="#">shared clinical decision-making</a>.  <u>High Risk:</u> 3-dose series at 0, 1-2 &amp; 6 months (minimum age 10 years)</p> <p><b>Adults:</b>  <u>Routine Risk:</u> 2-dose series <math>\geq</math> 6 months apart through age 23*; use <a href="#">shared clinical decision-making</a>.  <u>High Risk:</u> 3-dose series at 0, 1-2 &amp; 6 months</p> <p>*To optimize rapid protection (e.g., for students starting college in less than 6 months), 3-dose series (0, 1–2 &amp; 6 months) may be administered.</p> <p>Timing Guides: <a href="#">Routine Risk (PDF)</a> or <a href="#">High Risk (PDF)</a></p>	<p><b>Children:</b>  <u>Routine Risk:</u> 2-dose series <math>\geq</math> 6 months apart at age 16-18*; use <a href="#">shared clinical decision-making</a>.  <u>High Risk:</u> 3-dose series at 0, 1-2 &amp; 6 months (minimum age 10 years)</p> <p><b>Adults:</b>  <u>Routine Risk:</u> 2-dose series <math>\geq</math> 6 months through age 23*; use <a href="#">shared clinical decision-making</a>.  <u>High Risk:</u> 3-dose series 0, 1-2 &amp; 6 months</p> <p>*To optimize rapid protection (e.g., for students starting college in less than 6 months), 3-dose series (0, 1–2 &amp; 6 months) may be administered.</p> <p>Timing Guides: <a href="#">Routine Risk (PDF)</a> or <a href="#">High Risk (PDF)</a></p>
<b>Minimum Intervals</b>	<p>2-dose series: 6 months between dose 1 &amp; 2</p> <p>3-dose series:</p> <ul style="list-style-type: none"> <li>• 1 month between dose 1 &amp; 2</li> <li>• 4 months between dose 2 &amp; 3</li> <li>• 6 months between dose 1 &amp; 3</li> </ul>	<p>2-dose series: 6 months between dose 1 &amp; 2</p> <p>3-dose series:</p> <ul style="list-style-type: none"> <li>• 1 month between dose 1 &amp; 2</li> <li>• 4 months between dose 2 &amp; 3</li> <li>• 6 months between dose 1 &amp; 3</li> </ul>
<b>Administration</b>	Intramuscular (IM) injection	Intramuscular (IM) injection
<b>Packaging</b>	Vaccine packaged as 10 single-dose 0.5mL syringes or 1 single-dose 0.5mL syringe per carton	Vaccine packaged as 10 single-dose 0.5mL syringes or 5 single-dose 0.5mL syringes
<b>Storage</b>	Refrigerate between 36°F and 46°F (2°C to 8°C) - <b>Do not freeze</b>	Refrigerate between 36°F and 46°F (2°C to 8°C) - <b>Do not freeze</b>

## Vaccine Fact Sheet: MenB

Topic	BEXSERO®	TRUMENBA®
Recommendations	<a href="#">Meningococcal Vaccine (ACIP)</a>	<a href="#">Meningococcal Vaccine (ACIP)</a>
Program Letter	<a href="#">VFC Clinical Letter (PDF)</a>	<a href="#">VFC Clinical Letter (PDF)</a>
Billing Codes	CPT code for vaccine: 90620 CPT code for administration: 90640 Medi-Cal Fee-For-Service (FFS) administration for VFC supplied vaccine: 90620-SL (for ages 16 through 18 years); 90620-SL and –SK for high-risk persons 10 through 15 years). ICD-10-CM code (encounter for immunization): Z23	CPT code for vaccine: 90620 CPT code for administration: 90640 Medi-Cal Fee-For-Service (FFS) administration for VFC supplied vaccine: 90620-SL (for ages 16 through 18 years); 90620-SL and –SK for high-risk persons 10 through 15 years). ICD-10-CM code (encounter for immunization): Z23
Comments	Licensed in 2015	Licensed in 2014

<sup>1</sup> MenB vaccine brands are not interchangeable.

Refer to [Vaccine Fact Sheets](http://EZIZ.org/Resources/VaccineFactSheets) (EZIZ.org/Resources/VaccineFactSheets).